Companies / Jazz Pharmaceuticals
Jazz Pharmaceuticals Pipeline
CompanyJazz Pharmaceuticals is a biopharmaceutical company that develops and commercializes medicines across neuroscience, oncology and other serious diseases. It operates internationally and is headquartered in Dublin, Ireland.
Continuously tracked·last revised
Data: CSV·JSON·Browse the trials
Follow Jazz Pharmaceuticals
Email me when this page changes — new trials, changes of phase or status, and results as they are posted.
No mail is going out yet — your address is recorded now, used for nothing else, and never shared.
Thanks — your request is recorded. No mail is sent yet.
That did not work. Check the address and try again.
Recruiting Phase 3
Recently started
| Trial | Phase | Status | Sponsor | Started |
|---|---|---|---|---|
| Zanidatamab Outcomes and Lived Experiences in Advanced HER2+ GEA NCT07780968 | Phase unknown | Not yet recruiting | Jazz Pharmaceuticals | Started 2026-10 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JZP269 in Healthy Male and Female Participants NCT07813663 | Phase 1 | Not yet recruiting | Jazz Pharmaceuticals | Started 2026-09 |
| A Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of Juvenile Myoclonic Epilepsy NCT07723963 | Phase 2/3 | Not yet recruiting | Jazz Pharmaceuticals | Started 2026-09 |
| A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma NCT07533942 | Phase 2 | Recruiting | Jazz Pharmaceuticals | Started 2026-07 |
| A Study Evaluating the Efficacy and Safety of Xywav Expanded Dosing vs Placebo in Participants With Narcolepsy or IH NCT07625280 | Phase 3 | Recruiting | Jazz Pharmaceuticals | Started 2026-07 |
Results recently posted
Pipeline
Phase by status
| Phase | Recruiting | Not yet | Active | Completed | Terminated | Withdrawn | Unknown | Approved for marketing | No longer available | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Early Phase 1 | — | — | — | 1 | — | — | — | — | — | 1 |
| Phase 1 | 4 | 1 | 1 | 19 | 4 | — | — | — | — | 29 |
| Phase 1/2 | 1 | — | — | 4 | 1 | 1 | 1 | — | — | 8 |
| Phase 2 | 5 | — | — | 36 | 11 | 7 | — | — | — | 59 |
| Phase 2/3 | — | 1 | — | 1 | 1 | 1 | — | — | — | 4 |
| Phase 3 | 4 | 1 | 1 | 55 | 9 | — | — | — | — | 70 |
| Phase 4 | — | 1 | 1 | 6 | — | 2 | — | — | — | 10 |
| Unknown | 1 | 1 | 2 | 10 | 2 | — | 1 | 4 | 4 | 25 |
Trials started per year
Conditions studied, by phase
| Condition | Early Phase 1 | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | Phase 4 | Unknown | Total |
|---|---|---|---|---|---|---|---|---|---|
| Pain | — | — | — | 1 | — | 17 | — | — | 18 |
| Narcolepsy | — | 1 | — | 3 | — | 7 | 3 | 3 | 17 |
| Epilepsy | — | 1 | — | 9 | — | 6 | — | — | 16 |
| Multiple Sclerosis | — | — | — | — | — | 14 | 1 | 1 | 16 |
| Leukemia, Myeloid, Acute | 1 | 4 | — | 5 | — | 2 | — | 2 | 14 |
| Seizures | — | 1 | — | 3 | — | 4 | 1 | 2 | 11 |
| Muscle Spasticity | — | — | — | — | — | 9 | 1 | — | 10 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | — | 1 | — | 5 | 1 | — | — | 1 | 8 |
| Epilepsies, Myoclonic | — | — | — | 1 | — | 4 | 1 | 1 | 7 |
| Glioma | — | 2 | — | 1 | — | 1 | — | 3 | 7 |
Most active sponsors
| # | Sponsor | Trials | Phase 3 |
|---|---|---|---|
| 1 | Jazz Pharmaceuticals | 206 | 74 |
Frequent collaborators
| # | Collaborator | Trials |
|---|---|---|
| 1 | Jazz Pharmaceuticals Ireland Limited | 10 |
| 2 | Oncoceutics, Inc. | 5 |
| 3 | Jazz Pharmaceuticals Research UK Limited | 4 |
| 4 | Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 |
| 5 | BeOne Medicines LTD | 2 |
| 6 | Chimerix, Inc. | 2 |
| 7 | GW Pharmaceuticals Ltd | 2 |
| 8 | National Institutes of Health (NIH) | 2 |
| 9 | The Leukemia and Lymphoma Society | 2 |
| 10 | Translational Drug Development | 2 |
Most studied interventions
| # | Intervention | Trials |
|---|---|---|
| 1 | nabiximols | 37 |
| 2 | Cannabidiol | 27 |
| 3 | brincidofovir | 17 |
| 4 | CPX-351 | 13 |
| 5 | zanidatamab | 12 |
| 6 | Sodium Oxybate | 11 |
| 7 | TIC10 compound | 10 |
| 8 | solriamfetol | 9 |
| 9 | defibrotide | 5 |
| 10 | PM 01183 | 5 |
Terminations
Stated reasons
Reasons are grouped from the sponsor's own wording with a rule-based classifier; the original text is shown below.
Recently stopped
| Trial | Status | Stated reason | Stopped |
|---|---|---|---|
| NCT06961266 Terminated | Terminated | The study was terminated based on a business decision by the Sponsor. | 2026-01-29 |
| NCT04485104 Terminated | Terminated | The study was terminated by the Sponsor due to low patient enrollment. | 2025-01-28 |
| NCT05631327 Terminated | Terminated | The study was terminated based on a business decision by the Sponsor. | 2024-04-24 |
| NCT05126433 Terminated | Terminated | Termination of this study was a business decision made during portfolio review. | 2023-12-20 |
| NCT05733390 Withdrawn | Withdrawn | A decision has been made to prioritize other pipeline programs and terminate this study. | 2023-11-09 |
| NCT05288283 Terminated | Terminated | The study was terminated due to a business decision. | 2023-09-28 |
| NCT03295396 Terminated | Terminated | The Sponsor terminated the study to prioritize enrollment in a randomized Phase 3 trial of ONC201 in an earlier setting. This decision was unrelated to any safety concerns with dordaviprone (ONC201). | 2023-07-19 |
| NCT03416530 Terminated | Terminated | The Sponsor terminated the study to prioritize enrollment in a randomized Phase 3 trial of ONC201 in an earlier setting. This decision was unrelated to any safety concerns with dordaviprone (ONC201). | 2023-05-24 |
| NCT02525692 Terminated | Terminated | The Sponsor terminated the study to prioritize enrollment in a randomized Phase 3 trial of ONC201 in an earlier setting. This decision was unrelated to any safety concerns with dordaviprone (ONC201). | 2023-04-17 |
| NCT04203498 Terminated | Terminated | This study was terminated based on a business decision by the Sponsor. | 2023-02-28 |
Evidence
- Results reported
- 84.1%111 of 132 completed
- Published
- 23.5%31 of 132 completed
- Primary endpoint met
- 41.9%39 of 93 analyses
- Median months to report
- 26
Documents disclosed
Trial profile
- Median enrollment
- 92
- Median duration
- 23.2months
- Countries
- 49
- Study sites
- 3243
Who is enrolled
Median enrollment by phase
- Early Phase 1
- 10
- Phase 1
- 36
- Phase 1/2
- 25
- Phase 2
- 51
- Phase 2/3
- 128
- Phase 3
- 173
- Phase 4
- 71
- Unknown
- 158
Where trials run
Busiest cities
| # | City | Country | Trials |
|---|---|---|---|
| 1 | Houston | United States | 59 |
| 2 | New York | United States | 56 |
| 3 | Los Angeles | United States | 52 |
| 4 | Chicago | United States | 50 |
| 5 | Philadelphia | United States | 46 |
| 6 | Boston | United States | 45 |
| 7 | Cincinnati | United States | 45 |
| 8 | Atlanta | United States | 44 |
| 9 | St Louis | United States | 40 |
| 10 | Seattle | United States | 34 |